iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 582 participants.
Also called NCT05413369
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 582 participants
- Sponsor
- Registry
-
NCT05413369 -
U1111-1267-2772
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05413369. Randomized; no masking; primary purpose treatment. Start 2022-07-07 (actual); primary completion 2023-10-20 (actual). Results posted on 2024-10-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine/Lixisenatide
- Intervention (Drug)
- IDegAsp
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- SGLT2 inhibitor
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct05413369- Content hash
3659f17a7d7e33f1a0d47a4ed0448dcdbb03a8d457ac837626ca024c1b9d748f